Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer
Shots:
- The P-III KEYNOTE-522 study involves assessing of Keytruda + CT vs PBO + CT as neoadjuvant therapy- followed Keytruda vs PBO as adjuvant therapy in 1-174 patients in a ratio (2:1) with TNBC
- The P-III KEYNOTE-522 study resulted in meeting its one of the dual 1EPs i.e- improvement in pCR rates regardless of PD-L1 status- safe and tolerable- no new safety signals were observed
- Keytruda is an anti-PD-1 therapy- blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 and activated T-lymphocytes affecting both tumor and healthy cells- being evaluated in three ongoing studies for TNBC (KEYNOTE-355- KEYNOTE-242 and KEYNOTE-522)
Click here to read full press release/ article
Ref: Merck | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com